Expanded Access Use of Dupilumab

Learn more about:
Related Clinical Trial
Expanded Access Use of Dupilumab Transcriptomic Landscape of T Lymphocytes of Atopic Dermatitis, Atopic Prurigo Nodularis (of Besnier) and Non-atopic Prurigo Nodularis (of Hyde) Using Single Cell RNA-sequencing A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) An Efficacy and Safety Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis Safety and Efficacy of Nemolizumab in PN Effectiveness of the Selective Serotonin Reuptake Inhibitor,Citalopram (Cipralex), in Prurigo Nodularis Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis Evaluation of the Antipruritic Effect of Elidel (Pimecrolimus) in Non-atopic Pruritic Disease Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch) Pain Outcomes Following Intralesional Corticosteroid Injections A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN) A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Prurigo Nodularis Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis Apremilast as Anti-pruritic Treatment in Patients With Prurigo Nodularis PRISM Study-Pruritus Relief Through Itch Scratch Modulation Safety and Efficacy of CC-10004 for Prurigo Nodularis Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis

Brief Title

Compassionate Use of Dupilumab


Brief Summary

      Provide Compassionate Use of Dupilumab
    

Detailed Description

      Compassionate Use requests are only being considered in response to Individual Patient
      Investigational New Drug (IND) applications. Availability will depend on location.
    


Study Type

Expanded Access




Condition

Bullous Pemphigoid

Intervention

Dupilumab


Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug







Ages

 - 


Contacts

, 844-734-6643, [email protected]



Administrative Informations


NCT ID

NCT04776694

Organization ID

R668-Dupilumab


Responsible Party

Sponsor

Study Sponsor

Regeneron Pharmaceuticals


Study Sponsor

, , 


Verification Date

June 2021